Here is an article saying blocking ccr5 promotes cancer fighting.
https://www.cell.com/cancer-cell/fulltext/S15...16)30087-3
I like this guys description better of the article better (though maybe not as accurate)
https://adventuresinlivingterminallyoptimisti...maraviroc/
The comments in that blog linked above are interesting , some people saying the insurance is covering maraviroc based on the phase 1 results.
https://www.cell.com/cancer-cell/fulltext/S15...16)30087-3
Quote:This mechanism can be targeted effectively in human cancer patients by blocking CCR5, which also leads to anti-tumoral repolarization of macrophages . This work reveals a pro-tumorigenic mechanism involving components of the immune system that are exploited effectively in metastases to promote tumor growth and invasion. Translation into a clinical trial confirmed the therapeutic efficacy of CCR5 blockade, especially in mitigating this pro-tumor inflammatory microenvironment through effects on both tumor cells and tumor-associated macrophages.
I like this guys description better of the article better (though maybe not as accurate)
https://adventuresinlivingterminallyoptimisti...maraviroc/
Quote:One of the cell types in the innate immune system is the macrophage. Macrophages can either be tumor fighting (“M1-subtype”) or tumor helping (“M2-subtype”). Discovering ways to control macrophages and switch which sub-type they are is an intense area of current research.
In CRC, macrophages within the tumor (“tumor-associated macrophages (TAMs)”) are often of the “tumor promoting” M2-subtype. An area of active research has been to switch (or as scientists say, “repolarize”) these macrophages into M1-subtype tumor fighters. As M1-subtype tumor fighters and members of the innate immune system, macrophages can either attack cancer cells directly or serve as intermediaries to facilitate attack by the adaptive immune system.
Scientists have discovered that one of the master switches for determining whether a macrophage is tumor promoting (M2-subtype) vs. tumor fighting (M1-subtype) is the “CCR5 receptor”. This research has been recently published in the journal Cancer Cell. The exciting thing is that by blocking the CCR5 receptor with a CCR5 antagonist (e.g. Maraviroc), tumor promoting (M2-subtype) macrophages in CRC metastases can be switched (“repolarized”) into M1-subtype tumor fighters!
The comments in that blog linked above are interesting , some people saying the insurance is covering maraviroc based on the phase 1 results.
